Alibaba's Historic $2.8bn Fine Signals Coming Antitrust Wave In China
Pharma Industry Group Prioritizes Compliance
China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. Past cases show the pharma sector is not immune and while it remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.
